Overview

An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years

Status:
Completed
Trial end date:
2012-11-16
Target enrollment:
Participant gender:
Summary
This observational study will characterize retrospectively patients with HER2-positive metastatic or locally advanced breast cancer who had received treatment with Herceptin (trastuzumab) in 1st line and who were without progression for at least three years. Patients will be followed prospectively for one year.
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Trastuzumab